company background image
2500

Venus Medtech (Hangzhou) SEHK:2500 Stock Report

Last Price

HK$17.50

Market Cap

HK$7.7b

7D

0.7%

1Y

-73.3%

Updated

02 Jul, 2022

Data

Company Financials +
2500 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

2500 Stock Overview

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally.

Venus Medtech (Hangzhou) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Venus Medtech (Hangzhou)
Historical stock prices
Current Share PriceHK$17.50
52 Week HighHK$66.25
52 Week LowHK$10.52
Beta-0.20
1 Month Change29.44%
3 Month Change17.14%
1 Year Change-73.26%
3 Year Changen/a
5 Year Changen/a
Change since IPO-59.35%

Recent News & Updates

Shareholder Returns

2500HK Medical EquipmentHK Market
7D0.7%-2.8%0.5%
1Y-73.3%-58.8%-20.3%

Return vs Industry: 2500 underperformed the Hong Kong Medical Equipment industry which returned -58.8% over the past year.

Return vs Market: 2500 underperformed the Hong Kong Market which returned -20.3% over the past year.

Price Volatility

Is 2500's price volatile compared to industry and market?
2500 volatility
2500 Average Weekly Movement11.2%
Medical Equipment Industry Average Movement9.1%
Market Average Movement6.9%
10% most volatile stocks in HK Market13.7%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 2500 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 2500's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2009905Eric Zihttps://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company’s products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension.

Venus Medtech (Hangzhou) Fundamentals Summary

How do Venus Medtech (Hangzhou)'s earnings and revenue compare to its market cap?
2500 fundamental statistics
Market CapCN¥6.54b
Earnings (TTM)-CN¥373.64m
Revenue (TTM)CN¥415.86m

15.7x

P/S Ratio

-17.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2500 income statement (TTM)
RevenueCN¥415.86m
Cost of RevenueCN¥91.52m
Gross ProfitCN¥324.34m
Other ExpensesCN¥697.98m
Earnings-CN¥373.64m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin77.99%
Net Profit Margin-89.85%
Debt/Equity Ratio0.1%

How did 2500 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 2500 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2500?

Other financial metrics that can be useful for relative valuation.

2500 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.7x
Enterprise Value/EBITDA-14.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 2500's PS Ratio compare to its peers?

2500 PS Ratio vs Peers
The above table shows the PS ratio for 2500 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average11.5x
1858 Beijing Chunlizhengda Medical Instruments
3.9xn/aHK$7.9b
1696 Sisram Medical
2.7x17.8%HK$6.3b
2160 MicroPort CardioFlow Medtech
32x36.7%HK$7.5b
1789 AK Medical Holdings
7.4x26.8%HK$6.6b
2500 Venus Medtech (Hangzhou)
15.7x30.1%HK$7.7b

Price-To-Sales vs Peers: 2500 is expensive based on its Price-To-Sales Ratio (15.7x) compared to the peer average (11.5x).


Price to Earnings Ratio vs Industry

How does 2500's PE Ratio compare vs other companies in the HK Medical Equipment Industry?

Price-To-Sales vs Industry: 2500 is expensive based on its Price-To-Sales Ratio (15.7x) compared to the Hong Kong Medical Equipment industry average (6.9x)


Price to Sales Ratio vs Fair Ratio

What is 2500's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2500 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.7x
Fair PS Ratio13.1x

Price-To-Sales vs Fair Ratio: 2500 is expensive based on its Price-To-Sales Ratio (15.7x) compared to the estimated Fair Price-To-Sales Ratio (13.1x).


Share Price vs Fair Value

What is the Fair Price of 2500 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2500's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2500's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2500's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Venus Medtech (Hangzhou) forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


48.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2500 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2500 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2500 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2500's revenue (30.1% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).

High Growth Revenue: 2500's revenue (30.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2500 is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Venus Medtech (Hangzhou) performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-6.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 2500 is currently unprofitable.

Growing Profit Margin: 2500 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2500 is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare 2500's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2500 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).


Return on Equity

High ROE: 2500 has a negative Return on Equity (-8.02%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Venus Medtech (Hangzhou)'s financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 2500's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥208.5M).

Long Term Liabilities: 2500's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥269.1M).


Debt to Equity History and Analysis

Debt Level: 2500 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 2500's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2500 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 2500 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30.7% each year


Discover healthy companies

Dividend

What is Venus Medtech (Hangzhou) current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2500's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2500's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2500's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2500's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2500 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Eric Zi (52 yo)

9.67yrs

Tenure

Mr. Zhenjun Zi, also known as Eric, is Founder and Managing Partner at DiNovA Venture Capital. Prior to this, Mr. Zi served as Business Development & Strategic Planning Director at Lifetech Scientific Corp...


Leadership Team

Experienced Management: 2500's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: 2500's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Venus Medtech (Hangzhou) Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Venus Medtech (Hangzhou) Inc.
  • Ticker: 2500
  • Exchange: SEHK
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: HK$7.663b
  • Shares outstanding: 437.90m
  • Website: https://www.venusmedtech.com

Number of Employees


Location

  • Venus Medtech (Hangzhou) Inc.
  • No. 88, Jiangling Road
  • 3rd Floor
  • Hangzhou
  • Zhejiang Province
  • 31005
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/02 00:00
End of Day Share Price2022/06/30 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.